Cited 5 time in
Susceptibility to Fosfomycin and Nitrofurantoin of ESBL-Positive Escherichia coli and Klebsiella pneumoniae Isolated From Urine of Pediatric Patients
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Park, Ki-Sup | - |
| dc.contributor.author | Kim, Doo Ri | - |
| dc.contributor.author | Baek, Jin Yang | - |
| dc.contributor.author | Shin, Areum | - |
| dc.contributor.author | Kim, Kyung-Ran | - |
| dc.contributor.author | Park, Hwanhee | - |
| dc.contributor.author | Son, Sohee | - |
| dc.contributor.author | Cho, Heeyeon | - |
| dc.contributor.author | Kim, Yae-Jean | - |
| dc.date.accessioned | 2023-12-27T06:30:22Z | - |
| dc.date.available | 2023-12-27T06:30:22Z | - |
| dc.date.issued | 2023-12 | - |
| dc.identifier.issn | 1011-8934 | - |
| dc.identifier.issn | 1598-6357 | - |
| dc.identifier.uri | https://scholarworks.gnu.ac.kr/handle/sw.gnu/69014 | - |
| dc.description.abstract | BACKGROUND: Pediatric urinary tract infection (UTI) caused by extended-spectrum β-lactamase (ESBL)-positive gram-negative bacilli (GNB) has limited options for oral antibiotic treatment. The purpose of this study was to investigate the susceptibility of ESBL-positive Escherichia coli and Klebsiella pneumoniae isolates from pediatric urine samples to two oral antibiotics (fosfomycin and nitrofurantoin). METHODS: From November 2020 to April 2022, ESBL-positive E. coli and K. pneumoniae isolates from urine samples were collected at Samsung Medical Center, Seoul, Korea. Patients over 18 years of age or with malignancy were excluded. For repeated isolates from the same patient, only the first isolate was tested. Minimum inhibitory concentrations (MICs) were measured using agar (fosfomycin) or broth (nitrofurantoin) dilution methods. MIC50 and MIC90 were measured for fosfomycin and nitrofurantoin in both E. coli and K. pneumoniae. RESULTS: There were 117 isolates from 117 patients, with a median age of 7 months (range, 0.0-18.5 years). Among 117 isolates, 92.3% (108/117) were E. coli and 7.7% (9/117) were K. pneumoniae. Isolates from the pediatric intensive care unit (PICU) and general ward (GW) was 11.1% (13/117) and 88.9% (104/117), respectively. Among 108 E. coli isolates, MIC50 and MIC90 for fosfomycin were 0.5 μg/mL and 2 μg/mL, respectively. Fosfomycin susceptibility rate was 97.2% (105/108) with a breakpoint of 128 μg/mL. Fosfomycin susceptibility rate was significantly lower in PICU isolates than in GW isolates (81.8% vs. 99.0%, P = 0.027). For nitrofurantoin, both the MIC50 and MIC90 were 16 μg/mL. Nitrofurantoin susceptibility rate was 96.3% (104/108) with a breakpoint of 64 μg/mL based on Clinical and Laboratory Standards Institute guidelines. Among the nine K. pneumoniae isolates, the MIC50 and MIC90 for fosfomycin was 2 μg/mL and 32 μg/mL, respectively. MIC50 and MIC90 for nitrofurantoin were 64 μg/mL and 128 μg/mL, respectively. CONCLUSION: For uncomplicated UTI caused by ESBL-positive GNB in Korean children, treatment with fosfomycin and nitrofurantoin for E. coli infections can be considered as an effective oral therapy option. © 2023 The Korean Academy of Medical Sciences. | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | 대한의학회 | - |
| dc.title | Susceptibility to Fosfomycin and Nitrofurantoin of ESBL-Positive Escherichia coli and Klebsiella pneumoniae Isolated From Urine of Pediatric Patients | - |
| dc.title.alternative | Susceptibility to Fosfomycin and Nitrofurantoin of ESBL-Positive Escherichia coli and Klebsiella pneumoniae Isolated From Urine of Pediatric Patients | - |
| dc.type | Article | - |
| dc.publisher.location | 대한민국 | - |
| dc.identifier.doi | 10.3346/jkms.2023.38.e361 | - |
| dc.identifier.scopusid | 2-s2.0-85179639813 | - |
| dc.identifier.wosid | 001125213300003 | - |
| dc.identifier.bibliographicCitation | Journal of Korean Medical Science, v.38, no.48, pp e361 - 9 | - |
| dc.citation.title | Journal of Korean Medical Science | - |
| dc.citation.volume | 38 | - |
| dc.citation.number | 48 | - |
| dc.citation.startPage | e361 | - |
| dc.citation.endPage | 9 | - |
| dc.type.docType | Article | - |
| dc.identifier.kciid | ART003022475 | - |
| dc.description.isOpenAccess | Y | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.description.journalRegisteredClass | kci | - |
| dc.relation.journalResearchArea | General & Internal Medicine | - |
| dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
| dc.subject.keywordPlus | IN-VITRO ACTIVITY | - |
| dc.subject.keywordPlus | TRACT-INFECTION | - |
| dc.subject.keywordPlus | RESISTANT | - |
| dc.subject.keywordPlus | INFANTS | - |
| dc.subject.keywordAuthor | Fosfomycin | - |
| dc.subject.keywordAuthor | Nitrofurantoin | - |
| dc.subject.keywordAuthor | Pediatric | - |
| dc.subject.keywordAuthor | Urinary Tract Infection | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
Gyeongsang National University Central Library, 501, Jinju-daero, Jinju-si, Gyeongsangnam-do, 52828, Republic of Korea+82-55-772-0534
COPYRIGHT 2022 GYEONGSANG NATIONAL UNIVERSITY LIBRARY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
